GeneDx Holdings Corp. $WGS is Casdin Capital LLC’s Largest Position

Casdin Capital LLC trimmed its holdings in GeneDx Holdings Corp. (NASDAQ:WGS) by 14.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,007,164 shares of the company’s stock after selling 500,000 shares during the quarter. GeneDx makes up about 27.0% of Casdin Capital LLC’s portfolio, making the stock its biggest position. Casdin Capital LLC owned 0.10% of GeneDx worth $323,992,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of WGS. Royal Bank of Canada boosted its holdings in GeneDx by 30.2% during the 1st quarter. Royal Bank of Canada now owns 29,479 shares of the company’s stock valued at $2,611,000 after acquiring an additional 6,840 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in GeneDx by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,641 shares of the company’s stock worth $677,000 after purchasing an additional 453 shares during the period. NewEdge Advisors LLC increased its stake in GeneDx by 270,700.0% in the first quarter. NewEdge Advisors LLC now owns 2,708 shares of the company’s stock worth $240,000 after purchasing an additional 2,707 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of GeneDx by 67.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 28,224 shares of the company’s stock worth $2,500,000 after purchasing an additional 11,375 shares during the last quarter. Finally, Envestnet Asset Management Inc. lifted its position in shares of GeneDx by 63.9% during the second quarter. Envestnet Asset Management Inc. now owns 14,942 shares of the company’s stock worth $1,379,000 after purchasing an additional 5,823 shares during the last quarter. 61.72% of the stock is owned by institutional investors.

GeneDx Price Performance

Shares of WGS stock opened at $77.78 on Friday. GeneDx Holdings Corp. has a twelve month low of $55.17 and a twelve month high of $170.87. The company has a current ratio of 2.46, a quick ratio of 2.34 and a debt-to-equity ratio of 0.16. The stock has a fifty day simple moving average of $96.27 and a two-hundred day simple moving average of $120.81. The stock has a market capitalization of $2.28 billion, a price-to-earnings ratio of -103.71 and a beta of 2.03.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings results on Monday, February 23rd. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.11 by $0.03. The firm had revenue of $120.99 million for the quarter, compared to analyst estimates of $120.80 million. GeneDx had a positive return on equity of 14.73% and a negative net margin of 4.92%. On average, analysts predict that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on WGS shares. Zacks Research upgraded shares of GeneDx from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 25th. Wall Street Zen lowered shares of GeneDx from a “buy” rating to a “hold” rating in a report on Sunday, February 8th. Piper Sandler reissued an “overweight” rating and issued a $130.00 price objective (down from $160.00) on shares of GeneDx in a research report on Tuesday, February 24th. Weiss Ratings restated a “sell (d)” rating on shares of GeneDx in a research note on Wednesday, January 21st. Finally, BTIG Research reduced their target price on shares of GeneDx from $200.00 to $170.00 and set a “buy” rating on the stock in a research report on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $150.71.

Insider Buying and Selling at GeneDx

In other GeneDx news, COO Bryan Dechairo sold 5,961 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $85.70, for a total transaction of $510,857.70. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Katherine Stueland sold 25,459 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $78.61, for a total transaction of $2,001,331.99. Following the completion of the sale, the chief executive officer owned 38,683 shares of the company’s stock, valued at approximately $3,040,870.63. This represents a 39.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 57,702 shares of company stock valued at $5,640,255 in the last 90 days. Insiders own 29.60% of the company’s stock.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.